## TUMOR-REACTIVE TIL WITH AN EXHAUSTED PHENOTYPE CAN BE EXPANDED AND REGRESS HUMAN TUMORS

PRECLINICAL PDX DATA

Session Title: Late-Breaking Research: Immunology 1 Session Date and Time: Sunday Apr 7, 2024 1:30 PM - 5:00 PM **Location:** Poster Section 54 **Poster Board Number:** 3 **Abstract Presentation Number: LB067** 


Colin Thalhofer<sup>2</sup>, Ryan Montler<sup>2</sup>, Elaine Ballinger<sup>2</sup>, Jessica Cross<sup>2</sup>, Nicholas Morris<sup>2</sup>, Eric Tran<sup>1</sup>, Nelson Sanjuan<sup>1</sup>, Matthew Taylor<sup>1</sup>, Christopher Fountain<sup>1</sup>, Roxanne Payne<sup>1</sup>, James Cardia<sup>3</sup>, **Brendan Curt**i<sup>1</sup>, **Andrew Weinberg**<sup>1,2</sup>

<sup>1</sup>Providence Cancer Institute, Portland, OR, <sup>2</sup>Agonox, Inc., Portland, OR, <sup>3</sup>Phio Pharmaceutical, Marlborough, MA



#### **SUMMARY**

Tumor-reactive human CD8+ CD39+ CD103+ (Double Positive, DP) T cells are predominantly found in the tumor microenvironment with an exhausted phenotype (significantly high levels of CD39, PD-1, CTLA-4, and TIM-3). Our unique expansion method allows these DP cells to grow from thousands into billions, traffic to the tumor site, recognize autologous tumor, and facilitate tumor regression. We tested the CD8 DP TIL in vivo using a xenograft model with immune-compromised mice that constitutively secrete human IL-2 (NOGhIL-2), which was necessary for the long-term survival of TIL in the periphery and for tumor regression. These preclinical data were the basis for our Phase 1 human clinical trial design for the adoptive transfer of CD8 DP TIL (AGX148). The trial is a first-in-human protocol for adults with solid tumors (NCT05902520) consisting of three cohorts: 2 weeks, 3 weeks, or 4 weeks of IL-2 administration after adoptive TIL transfer. Each cohort contains six patients; 3 receiving DP TIL alone and 3 receiving DP TIL with PD-1 siRNA knockdown using INTASYL<sup>TM</sup> compound PH-762. The first 3 patients have been treated; all previously failed standard therapy, including checkpoint blockade. No serious adverse events were observed. Two of the three patients had partial responses and the third patient had stable disease.



# **BACKGROUND** CD8+ TIL **TIL Autologous Tumor Reactivity** - DP IFN-γ % DP Across Tumor Types Adapted from: Duhen et al., Nat.Comm. 2018

CD8+ CD39+ CD103+ (DP) cells are found in a variety of tumor types and have a distinct exhausted phenotype compared to the DN. DP cells upregulate 4-1BB, CD25, and IFN-γ in tumor coculture; DN cells do not.



- Clinical Trials- Tracy Kelly, Shannon Erickson,
- **CRAD** Amanda Lyon, Traci Brotherton
- **CPF** Jessica Huang
- **Computational Immuno-oncology and**
- **IML** Iliana Gonzalez, Tanisha Christie,
- Yoshinobu Koguchi
- IHC- Zhaoyu Sun



#### Survival Experiment in NOG or hIL-2 NOG mice **Mouse Tumor Measurements** Tissue Harvest Survival Tumors Bleed (Day 8) Regressing Tumor Experiments in hIL-2 NOG mice Day 48 Tumor IHC (CD8) DP treated mice Blood vs. Tumor → IL-2 DN (n=8) — IL-2 DP (n=8) **End of Study Tissue Harvest** NOG DN IL-2 DN → DN

PRELIMINARY CLINICAL TRIAL RESULTS

#### **Product summary: First 3 patients** Patient 3: INTASYL<sup>TM</sup> PH-762 treated CD39 and CD103 expression of CD8+ T cells during clinical sort Day +80 Baseline Day +27 Patient 1 Patient 2 65% reduction Lesion 1: Popliteal LN, met 10<sup>5</sup> 10<sup>2</sup> 10<sup>3</sup> 10<sup>4</sup> 10<sup>5</sup> 10<sup>6</sup> Lesion 2: Left lateral knee, SQ met 100% reduction Sum of Target Lesions by RECIST criteria % of DP # DP cells sorted % Viability Fold Lesion 3: Left medial ankle, met Days post-infusion Immune Monitoring: Blood and TIL Product Phenotypes Patient 2 Patient 3 Patient 1 Non-Target Lesions: Left medial leg, SQ sites

High dose IL-2: Daily IV injection for 6 days, beginning on day of infusion (Day 0)

Late-stage IL-2, Pt 1 only: IV injection every 8hrs for 5 days for 15 total doses per round

CD39 CD103 subsets of CD8+

Patient 3 Phenotyping

PD-1

Gated on CD8+ CD39+ CD103+

**4-wk Tumor Biopsy** 

**Primary Expansion** 

**Infusion Product** 

**Primary Tumor** 

Gated on CD8+


Ki-67

■ 17% ■ 34% ■ 34% ■ 3 % ■ < 1% ■ 45% ■ 7%

GrzB

**HLA-DR** 

Low dose IL-2, Cohort 1: 5MIU/m<sup>2</sup> SQ injection 3X for one week





PD-1 expression for the product


(BLACK) vs non-INTAYSL<sup>TM</sup> PH-762


treated control (RED)

## DP SINGLE CELL GENE AND TCR-SEQ










### CONCLUSIONS

- CD8+ CD39 CD103 DP tumor-reactive TIL are found in a variety of solid tumor types at varying frequencies and have a significant "exhausted" phenotype.
- In pre-clinical PDX models, adoptively transferred DP TIL persisted long-term, trafficked to and cleared autologous tumors in the presence of IL-2.
- TCR-seq showed distinct TCR repertoire in the DP vs DN TIL.
- Single-cell TCR-seq and gene-seq demonstrated diversity of phenotypes within the DP TIL product.
- Using AgonOx's AGX148 selection and expansion method, DP TIL can be grown in vitro to billions of highly functional cells.
- AgonOx's AGX148 selected-TIL product minimizes bystander expansion and is highly enriched with tumor-reactive T cells.
- INTASYL<sup>TM</sup> PH-762 treatment reduced PD-1 protein expression on AGX148 TIL Product .
- Phenotype of blood and tumor biopsies revealed distinct phenotypic changes after TIL treatment in both humans and mice.
- Preliminary clinical trial results from 3 patients showed evidence of tumor regression at day +29 (2 PR (melanoma) and 1 SD (thyroid cancer) with 1 PR and 1 SD ongoing > 80 days.



- Bioinformatics- Venkatesh Rajamanickam
- Molecular Pathology Core

